ArticleScientific reports2025
A pilot study of tegafur-uracil maintenance on survival in patients with esophageal squamous cell carcinoma following definitive chemoradiotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little was known regarding the maintenance role in patients with ESCC.This study evaluates the impact of Tegafur-Uracil (UFUR) maintenance on survival in patients with ESCC following definitive concurrent chemoradiotherapy (dCCRT). Patients with pathologically confirmed ESCC and treated with dCCRT were analyzed retrospectively. Patients were stratified into UFUR (+) and UFUR (-) groups based on maintenance or not after dCCRT. Oncologic outcomes, including progression-free survival (PFS), overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS), were compared between the groups. Multivariate Cox regression analysis was performed to identify independent predictors of survival. A total of 198 ESCC patients were included into our study. UFUR maintenance significantly reduced the overall recurrence rate (55% vs. 74%, p = 0.009), primarily driven by a reduction in distant metastases (44% vs. 63%, p < 0.001). The UFUR (+) group demonstrated markedly improved median OS (37.3 vs. 18.6 months, p = 0.002) and PFS (28.3 vs. 15.2 months, p = 0.014). Superior LRFS and DMFS were observed in the UFUR (+) group than those in UFUR (-) group, accounting for 29.6 vs. 13.4 months (p = 0.002) and 33.3 vs. 19.0 months (p = 0.010), respectively. Subgroup analyses revealed that UFUR(+) provided consistent benefits across all stages and all dCCRT responses. Multivariate analysis identified UFUR maintenance as an independent predictor of survival, alongside tumor stage and response to dCCRT. UFUR maintenance significantly improves outcomes in patients with ESCC following dCCRT, which might be considered as part of personalized treatment strategies to optimize prognosis in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.